The Effect of Two Prokinetics in Patients With Functional Dyspepsia

NCT ID: NCT07096921

Last Updated: 2025-08-05

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 92 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-07-08
• Study Completion Date: 2026-03-19

Brief Summary

This prospective, double-blinded, randomized, multicenter study will compare the efficacy and safety of two prokinetic regimens in patients with Rome IV-diagnosed functional dyspepsia. Ninety-two patients will be randomized (1:1) to receive either mosapride 5 mg + DA-9701 30 mg or mosapride 5 mg + matching placebo, three times daily before meals for 4 weeks. The primary endpoint is the proportion of overall responders ("much improved" or "very much improved" on a 7-point Likert scale) at Week 4. Secondary endpoints include overall response at Week 2, change in NDI-K symptom scores and PSQI-K sleep quality scores at Week 4, and safety assessments via laboratory tests and adverse-event monitoring.

Detailed Description

A four-visit schedule: screening (Visit 1), randomization (Visit 2, same day), telephone follow-up at Week 2, and on-site assessment at Week 4. Screening includes informed consent, demographics, medical history, concomitant medications, labs, Rome IV questionnaire. Randomization uses opaque sealed envelopes generated by an independent statistician. Investigational products are dispensed in a double-dummy design to maintain blinding. Treatment compliance, vital signs, AEs collected at each contact. Efficacy via Likert scale, NDI-K, PSQI-K; safety via labs and AE reporting.

Conditions

Functional Dyspepsia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Experimental

Experimental: Mosapride citrate 5 mg + DA-9701 30 mg, Oral, 3 times/day, 30 min before meals for 4 weeks

Group Type: EXPERIMENTAL

Mosapride citrate 5 mg + DA-9701 30 mg

Intervention Type: DRUG

Experimental: Mosapride citrate 5 mg + DA-9701 30 mg, Oral, 3 times/day, 30 min before meals for 4 weeks

Placebo

Placebo Comparator: Mosapride citrate 5 mg + DA-9701 placebo, Oral, 3 times/day, 30 min before meals for 4 weeks

Group Type: PLACEBO_COMPARATOR

Mosapride citrate 5 mg + DA-9701 30 mg placebo

Intervention Type: DRUG

Placebo Comparator: Mosapride citrate 5 mg + DA-9701 placebo, Oral, 3 times/day, 30 min before meals for 4 weeks

Interventions

Mosapride citrate 5 mg + DA-9701 30 mg

Experimental: Mosapride citrate 5 mg + DA-9701 30 mg, Oral, 3 times/day, 30 min before meals for 4 weeks

Intervention Type: DRUG

Mosapride citrate 5 mg + DA-9701 30 mg placebo

Placebo Comparator: Mosapride citrate 5 mg + DA-9701 placebo, Oral, 3 times/day, 30 min before meals for 4 weeks

Intervention Type: DRUG

Other Intervention Names

Gasmotin Tab. 5mg + Motilitone Tab.; Gasmotin Tab. 5mg + Motilitone Tab. placebo

Eligibility Criteria

Inclusion Criteria

1. ≥19 years of age

2. Patients diagnosed with functional dyspepsia according to the Rome IV criteria, who can be classified as having postprandial distress syndrome

• Rome IV criteria for functional dyspepsia:

1. One or more of the following symptoms:

1. Uncomfortable postprandial fullness

2. Early satiation

3. Epigastric pain

4. Epigastric burning

2. No evidence of structural disease that could explain the symptoms

• Symptoms must have started at least 6 months before diagnosis and been present during the last 3 months

3. No history of gastrointestinal surgery

4. No organic lesions found on upper endoscopy within the past 3 months

5. Voluntarily signed informed consent to participate in this clinical trial

Exclusion Criteria

1. Patients with confirmed structural diseases on upper gastrointestinal endoscopy, such as esophageal stricture, ulcer stricture, esophagogastric varices, Barrett's esophagus, active peptic ulcer, gastrointestinal bleeding, or eosinophilic esophagitis

2. Patients who have undergone surgery involving the esophagus, stomach, or duodenum

3. Patients with abnormal values in blood chemistry tests within the past month:

• Total bilirubin, creatinine > 1.5 times the upper limit of normal (ULN)
• AST, ALT, alkaline phosphatase, BUN > 2 times the ULN

4. Patients with diabetic gastroparesis

5. Patients with a history of drug or alcohol abuse within the past year

6. Pregnant or breastfeeding women

-Patients currently taking medications that may affect the evaluation of the investigational drug's efficacy (e.g., acid-suppressing agents including PPIs, prokinetics, NSAIDs, anticholinergics, corticosteroids, antidepressants, erythromycin, mirtazapine, etc.) may only participate after a minimum 2-week wash-out period

7. Any other conditions that the investigator deems make the patient unsuitable for participation in the study

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Dong-A ST Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

Sponsor Role: collaborator

Eunpyeong St. Mary's Hospital

OTHER

Sponsor Role: lead

Responsible Party

OH JUNG HWAN

M.D., Ph.D.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

JUNG HWAN OH

Role: PRINCIPAL_INVESTIGATOR

The Catholic University of Korea Eunpyeong St. Mary's Hospital

Locations

The Catholic University of Korea, Eunpyeong St. Mary's Hospital

Seoul, Eunpyeong-gu, South Korea

Countries

South Korea

Other Identifiers

PC25MIDI0023

Identifier Type: -

Identifier Source: org_study_id